# Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

> **NCT05158140** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 850 (actual)

## Conditions studied

- Pneumococcal Infection

## Interventions

- **BIOLOGICAL:** V110
- **BIOLOGICAL:** V114
- **BIOLOGICAL:** mRNA-1273
- **BIOLOGICAL:** Placebo for V110
- **BIOLOGICAL:** Placebo for V114

## Key facts

- **NCT ID:** NCT05158140
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-12
- **Primary completion:** 2023-02-21
- **Final completion:** 2023-02-21
- **Target enrollment:** 850 (ACTUAL)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05158140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05158140, "Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05158140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*